The Asia Pacific Atopic Dermatitis Treatment market size was around USD 2.31 billion in 2018. It is expected to grow at a CAGR of 13.8% to reach USD 4.41 billion by 2023. It captures 25% of the global market share.
Atopic Dermatitis is a inflammatory skin disease. The degree of its severity varies from patient to patient. It usually begins in childhood and is mostly confined to the flexural surfaces of the body. It is highly prevalent. It is more commonly known as eczema. Itching, redness of skin, cracking, weeping etc. are symptoms of it. It is a long term disease. Low humidity, cold weather, seasonal allergies are the common causes of it. Pattern of the disease and its severity determine the kind of treatment it ought to receive.
Growing patient population, a lot of new product launches, climate change, and large pipeline products are the primary drivers of market growth.
Very strict regulations and generic competition are the primary restraints of market growth.
The market is categorized by route of administration, treatment type, and by distribution channel. If we go by treatment type the market is segregated into Drug treatment and Radiation treatment. Drug treatment is further sub-categorized into corticosteroids, emollients, antihistamines, calcineurin inhibitors and antibiotics. Corticosteroids capture the largest market share and are expected to retain their lead till the end of 2022. Classification by Route of administration is done into topical and oral. Topical leads the market and is likely to retain its lead in the aforementioned forecast period. Oral medicines are for patients with severe cases. Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies is the classification based on the distribution channels.
By geography the market is segmented into India, China, Korea, Japan, and others. Asia Pacific is predicted to be the fastest growing market in the aforementioned forecast period. Rapidly growing population, changing lifestyles and a paradigm shift towards western lifestyles, increasing R&D, and large target patient pool are the reasons attributable to the observable trend mentioned above.
Key players in the market are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Novartis International AG, Pfizer Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment Type
5.1.2 Drug Treatment
220.127.116.11 Calcineurin Inhibitors
5.1.3 Radiation Treatment
5.1.4 Y-o-Y Growth Analysis, By Treatment Type
5.1.5 Market Attractiveness Analysis, By Treatment Type
5.1.6 Market Share Analysis, By Treatment Type
5.2 Route of administration
5.2.4 Y-o-Y Growth Analysis, By Route of administration
5.2.5 Market Attractiveness Analysis, By Route of administration
5.2.6 Market Share Analysis, By Route of administration
5.3 Distribution Channel
5.3.2 Hospital Pharmacies
5.3.3 Retail Pharmacies
5.3.4 Online Pharmacies
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Treatment Type
126.96.36.199 By Route of administration
188.8.131.52 By Distribution Channel
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Treatment Type
18.104.22.168 By Route of administration
22.214.171.124 By Distribution Channel
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Treatment Type
184.108.40.206 By Route of administration
220.127.116.11 By Distribution Channel
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Astellas Pharma Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi S.A.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Novartis International AG
8.5 Pfizer Inc.
8.6 Meda Pharmaceuticals
8.7 Regeneron Pharmaceuticals Inc.
8.8 Anacor Pharmaceuticals, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures